The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk trial, a multinational, double-blind, placebo-controlled study of 27,564 patients with established atherosclerosis treated with statins, investigated the efficacy of evolocumab vs. placebo for reducing CV-related death, MI, stroke, hospitalization for unstable angina or coronary (primary efficacy endpoint) and CV-related death, MI, or stroke (key secondary efficacy endpoint) (20). The gene discussed is PCSK9; the disease is stroke disorder.